Between tightly scheduled meetings, BioArctic’s CEO Gunilla Osswald welcomes us to the company’s premises in Stadshagen, Stockholm. The pace in the building is high – and that is no coincidence.
“2025 was an incredibly successful year. Across the board, really,” she notes.
After more than two decades of research and company building, BioArctic entered what the CEO describes as its growth era last year. The business is now profitable and can focus on the next step: expanding as a pharmaceutical company on several fronts.
BREAKING